** Shares of drug developer Acelyrin SLRN.O rise 17.05% to $2.54 premarket
** SLRN confirms that private affiliate of investor Tang Capital Partners, Concentra Biosciences, has proposed to acquire it for $3 per share in cash, a 38.2% premium to its last closing price
** The offer implies an equity value of about $300 million, according to Reuters calculations, plus a "contingent value right"
** The investor had a 5.3% stake in SLRN - filing
** Earlier this month, SLRN announced an agreement to merge with Alumis ALMS.O in an all-stock transaction
** SLRN shares have fallen nearly 38% since it reported mid-stage data from its thyroid eye disease drug in early January
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。